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Introduction: Pulmonary arterial hypertension (PAH) is a major cause of mortality in systemic sclerosis (SSc).
Screening guidelines for PAH recommend multiple investigations, including annual echocardiography, which
together have low specificity and may not be cost-effective. We sought to evaluate the predictive accuracy of
serum N-terminal pro-brain natriuretic peptide (NT-proBNP) in combination with pulmonary function tests (PFT)
(‘proposed’ algorithm) in a screening algorithm for SSc-PAH.
Methods: We evaluated our proposed algorithm (PFT with NT-proBNP) on 49 consecutive SSc patients with
suspected pulmonary hypertension undergoing right heart catherisation (RHC). The predictive accuracy of the
proposed algorithm was compared with existing screening recommendations, and is presented as sensitivity,
specificity, positive predictive value (PPV) and negative predictive value (NPV).
Results: Overall, 27 patients were found to have pulmonary hypertension (PH) at RHC, while 22 had no PH. The
sensitivity, specificity, PPV and NPV of the proposed algorithm for PAH was 94.1%, 54.5%, 61.5% and 92.3%,
respectively; current European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines achieved a
sensitivity, specificity, PPV and NPV of 94.1%, 31.8%, 51.6% and 87.5%, respectively. In an alternate case scenario
analysis, estimating a PAH prevalence of 10%, the proposed algorithm achieved a sensitivity, specificity, PPV and
NPV for PAH of 94.1%, 54.5%, 18.7% and 98.8%, respectively.
Conclusions: The combination of NT-proBNP with PFT is a sensitive, yet simple and non-invasive, screening strategy
for SSc-PAH. Patients with a positive screening result can be referred for echocardiography, and further confirmatory
testing for PAH. In this way, it may be possible to shift the burden of routine screening away from echocardiography.
The findings of this study should be confirmed in larger studies.* Correspondence: m.nikpour@unimelb.edu.au
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Systemic sclerosis (SSc) is a multisystem connective tis-
sue disease resulting in a number of end-organ compli-
cations due to the pathogenic processes of vasculopathy,
fibrosis and autoimmunity [1]. Systemic sclerosis-related
pulmonary arterial hypertension (SSc-PAH) is a particu-
larly severe complication, affecting approximately 10% of
SSc patients, and is one of the leading causes of mortal-
ity in these patients [2].
The early detection of SSc-PAH has emerged as an
essential component of disease management. A num-
ber of studies have demonstrated the significantly better
prognosis of patients presenting in lower World Health
Organization functional classes (WHO-FC) (that is I
and II), compared to patients presenting with more
advanced functional impairment (WHO-FC III or IV)
[3,4]. Other studies have suggested that early com-
mencement of therapy may delay the progression of
SSc-PAH, and lead to improvements in functional
class [5,6]. Recently, the benefits of screening for SSc-
PAH were observed in a study that showed a signifi-
cantly higher three-, five- and eight-year survival rate
in patients identified by a screening program compared
with patients diagnosed during the course of routine clin-
ical care, when symptoms and/or signs directed further
investigation (81%, 73% and 64% vs. 31%, 25% and 17%,
respectively) [7].
Right heart catherisation (RHC) is currently the only
confirmatory test for PAH, but its invasive nature makes
it unsuitable for screening. Instead, non-invasive screen-
ing strategies are used to risk-stratify patients for RHC.
Current guidelines recommend transthoracic echocardi-
ography (TTE), either with or without diffusing capacity
for carbon monoxide (DLCO), as the strategy of choice;
however, there are some important limitations with this
approach [8-10]. While echocardiography and DLCO
perform well when PAH is advanced, neither test has
sufficiently high sensitivity for the detection of early dis-
ease, nor for the exclusion of PAH [11]. Further, varia-
tions in echocardiography technique, the accuracy of
measurements and interpretation of results poses chal-
lenges for the clinician, especially in community-based
practice where the quality of echocardiography can be
variable. In fact, the systolic pulmonary artery pressure
at echocardiography (sPAPTTE) cannot be obtained in 20
to 39% of patients due to technical and patient-related
factors such as obesity or concomitant interstitial lung
disease (ILD) [12,13]. Lastly, the cost-effectiveness of
echocardiography-based screening remains to be evalu-
ated, and it may be improved by rationalising the use of
these screening tools.
We have previously proposed a ‘first-tier’ screening
algorithm for SSc-PAH utilising serum N-terminal
pro-brain natriuretic peptide (NT-proBNP) levels andpulmonary function tests (PFTs) [14]. NT-proBNP is an
easily measured biomarker released by cardiac myocytes
in response to increased ventricular wall stress. A number
of studies have reported the potential utility of NT-
proBNP in SSc-PAH, including the study by Allanore
et al. wherein a high NT-proBNP level (>97th percentile
of normal) identified SSc patients who went on to develop
pre-capillary pulmonary hypertension (pre-CPH) over a
median follow-up period of 29 months [15-18]. We dem-
onstrated that combining NT-proBNP and PFTs to select
patients with positive screening results for referral for
echocardiography had a high sensitivity and specificity
for SSc-PAH confirmed by subsequent RHC. This ap-
proach has the potential to shift the burden of routine
screening away from using echocardiography in every
patient to limiting its use in a more targeted fashion to as-
sist in the selection of patients for RHC.
For a screening algorithm for SSc-PAH to be validated,
it should be compared with the diagnostic gold standard
in an unselected group of SSc patients. In this case,
RHC would be required in every patient but this could
be difficult to do without selection bias as this test is not
without risk. In the first instance, we set out to evaluate
the predictive accuracy of the proposed screening algo-
rithm in a group of patients at risk of SSc-PAH and to
compare this with the screening guidelines recommended
by the Australian Scleroderma Cohort Study (ASCS) [19]
and European Society of Cardiology/European Respiratory




For this study, we included consecutive SSc patients
from the ASCS who were considered to be at high risk
for PAH according to the ASCS screening guidelines
and hence referred for RHC. We then evaluated the per-
formance of the ‘proposed algorithm’ and ESC/ERS
screening recommendations on this group of patients.
The ASCS is a prospective, multi-centre study of risk
and prognostic factors for cardiopulmonary outcomes
in SSc. All patients fulfil either American College of
Rheumatology (ACR) or Leroy and Medsger criteria
for SSc [20,21]. The ASCS has been approved by the
human research ethics committees of the 13 participating
Australian centres (St Vincent’s Hospital Melbourne,
Royal Perth Hospital, Royal Adelaide Hospital, Queen
Elizabeth Hospital, Sunshine Coast Rheumatology,
Prince Charles Hospital, John Hunter Hospital, Royal
Prince Alfred Hospital, Royal North Shore Hospital,
St George Hospital, Canberra Rheumatology, Monash
Medical Centre and The Menzies Research Institute
Tasmania), and patients provide written informed consent
at recruitment.
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excluded [14]. While there were no specific exclusion
criteria for the patients in this study, patients screen-
ing positive to the ASCS undergo careful adjudication
before progression to RHC where they have demon-
strated previous evidence of clinically relevant left heart
disease.
Terminology
Current ASCS recommendations are that all patients
undergo an annual clinical assessment, TTE and
PFTs. Any patient identified as having possible PAH
(sPAPTTE ≥40 mmHg, and/or DLCOcorr ≤50% pre-
dicted with forced vital capacity (FVC) >85%, and/or
fall in DLCOcorr ≥20% on the previous year, or unex-
plained dyspnoea), especially in the presence of
symptoms and without adequate explanation on high-
resolution computed tomography (HRCT) lung and/
or ventilation/perfusion (V/Q) scanning, undergoes
RHC [19].
Current ESC/ERS guidelines are based on TTE, and
recommend a lower-limit threshold value of a triscuspid
regurgitant velocity (TRV) >2.8 m/s or sPAPTTE >36
mmHg for consideration of RHC [8].
Based on current guidelines, PH was defined as a
mean pulmonary artery pressure (mPAP) ≥25 mmHg at
RHC; therefore, no PH was defined as mPAP <25 mmHg
[8]. Pre-CPH was defined as mean pulmonary artery
pressure (mPAP) >25 mmHg at rest and pulmonary ca-
pillary wedge pressure (PCWP) ≤15 mmHg. If the
PCWP exceeded 15 mmHg, disease of the left side of
the heart (LHD-PH), or post-capillary PH were diag-
nosed. PAH was defined as pre-capillary PH on RHC
with no more than mild ILD on HRCT, and a FVC, (li-
tres) >70% predicted. ILD-PH was defined as pre-CPH
with moderate or severe changes of ILD on HRCT with
FVC ≤70% predicted [12,22].
Cardiac and pulmonary assessments
TTE, PFTs and NT-proBNP were all determined within
one month of RHC. Left ventricular systolic and dia-
stolic function and right ventricular systolic function
were determined by two-dimensional TTE. sPAPTTE
was estimated by Doppler echocardiography at rest,
based on peak velocity of the tricuspid regurgitant jet
and estimation of right atrial pressure of 5 to 10 mmHg
based on the diameter and respiratory variation of the
inferior vena cava. TTE was performed only at tertiary
centres for SSc assessment. Pulmonary involvement was
assessed by PFTs and/or HRCT. HRCTs were reported as
no, mild, moderate or severe ILD by a radiologist based
on total extent of lung disease. All DLCOcorr (ml/mmHg/
min) values are reported as % of predicted values, cor-
rected for haemoglobin [23].Serum samples and NT-proBNP measurement
All patients had serum collected for NT-proBNP meas-
urement at the time of TTE and PFTs, which were
within one month of their RHC, and in cases of PAH,
prior to the commencement of advanced pulmonary
vasodilator therapy. Blood samples were collected at rest
into tubes containing EDTA. Samples were centrifuged
and stored at −80°C until used. NT-proBNP was mea-
sured using the Elecsys proBNP II sandwich immuno-
assay on the modular analytics E170 (Roche Diagnostics,
Mannheim, Germany). The measurement range of this
assay is between 5 pg/mL and 35000 pg/mL.
Proposed screening algorithm
As derived in our previous study, the proposed screening
algorithm is comprised of two components: PFTs (com-
ponent A) and NT-proBNP (component B) (Figure 1)
[14]. For ease of application, we have rounded the
screening cut points of PFT and NT-proBNP to the
nearest significant number. Therefore, component A is
present if DLCOcorr <70% with an FVC/DLCOcorr ≥1.8,
and component B is present if NT-proBNP ≥210 pg/ml.
In this model, the screen is ‘positive’ if either component
A, component B, or components A and B are present,
and a screen is ‘negative’ if both component A and com-
ponent B are absent. All patients with a positive screen
move on to transthoracic echocardiography together
with further tests such as lung HRCT, V/Q scanning and
six-minute walk test (6MWT) as clinically indicated, while
those who screen negative undergo repeat screening at
regular intervals. The purpose of echocardiography and
further tests is to evaluate contributing (for example, right
and left ventricular systolic or diastolic dysfunction, inter-
stitial lung disease and thromboembolic disease) and
prognostic factors (right ventricular dysfunction and peri-
cardial effusion) for pulmonary hypertension, on a case-
by-case basis, that may have resulted in a positive screen.
If no alternative explanation is found for a positive screen,
patients should undergo confirmatory RHC testing, re-
gardless of sPAPTTE at echocardiography.
Statistical analysis
Data are presented as means ± standard deviations (SD) for
continuous variables, and numbers (percentages or pro-
portions) for categorical variables, unless stated otherwise.
Normally distributed variables were compared using
the Student’s t test with unequal variances, whereas differ-
ences in frequency were determined using chi-square and
Fisher’s exact tests. The Kruskall-Wallis and Mann-
Whitney U test were used to compare the continuous
variables among the smaller PH groups. The predictive
accuracy of the proposed algorithm, which was also com-
pared with the accuracy of the ERS/ESC algorithm in the
same cohort, are presented as sensitivity, specificity, positive
SSc 
patient
DLCOcorr  70 % predicted
& FVC/DLCO    1.8
And/Or





Low likelihood of PAH
DLCOcorr  70 % predicted
& FVC/DLCO 1.8
And






Figure 1 A proposed screening model for systemic sclerosis-related pulmonary arterial hypertension (SSc-PAH). 6MWT, six-minute walk
test; DLCO, diffusion capacity of lungs to carbon monoxide (% predicted); FVC, forced vital capacity (% predicted); HRCT, high-resolution
computed tomography (of lung); NT-proBNP, N-terminal pro-brain natriuretic peptide (pg/ml); PFT, pulmonary function test.
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dence intervals (95% CIs). An ‘alternate case scenario’
analysis was also performed assuming a prevalence rate
for PAH of 10%, lower than that seen in this study. Two-
tailed P value ≤0.05 was considered statistically signifi-
cant. All statistical analyses were performed using STATA
12.1 (Statacorp, College Station, TX, USA).
Results
Study composition
RHC was performed in 49 SSc patients as a result of
their ASCS screening investigations (see Figure 2). Of
these, 27 were found to have PH at RHC, while 22
had no PH. Of those with PH, the majority had PAH(n = 17), whilst the remainder had ILD-PH (n = 6) and
LHD-PH (n = 4).
Table 1 outlines the results of the various ASCS
screening investigations that led to RHC. Of the 27 pa-
tients with PH, 23 (85%) screened positive on echocardi-
ography (sPAPTTE >40 mmHg), 11 (41%) screened
positive on both echocardiography and PFT, and in only 2
patients was PFT the only positive test. In the PAH group,
16/17 patients screened positive on echocardiography,
and 9/17 (53%) screened positive on both echocardiog-
raphy and PFT. There was only one patient in the PAH
group who had an unrecordable sPAPTTE; this patient had
a DLCOcorr of 44% predicted, and was found to have early
PAH (WHO FC II, mPAP of 26 mmHg at RHC).
Figure 2 Clinical breakdown of patients who underwent right heart catherisation (RHC). All patients screened positive to the current
Australian Scleroderma Cohort Study; (ASCS) screening guidelines. FVC, forced vital capacity; HRCT, high-resolution computed tomography; ILD,
interstitial lung disease; LHD, left heart disease; mPAP, mean pulmonary artery pressure; PAH, pulmonary arterial hypertension; PCWP, pulmonary
capillary wedge pressure; PH, pulmonary hypertension; SSc, systemic sclerosis; WHO, World Health Organization.
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The patient demographics and characteristics of patients
with PAH and no PH are compared in Tables 2 and 3;
the features of the LHD-PH and ILD-PH are also shown.
As can be seen, all the patients with PAH were female,
with trends towards being older at the times of diagnosis
of SSc and PAH. While a significantly greater propor-
tion of the PAH group had anti-centromere antibodies





sPAPTTE >40 mmHG 10 23
DLCO <50% and FVC >85% 3 12
Fall in DLCO <20% of previous year 0 1
Unexplained dyspnoea** 9 2
Low DLCO was only positive test 3 2
*Patients who screened positive to one or more components of the ASCS screening
neither the TTE nor PFT satisfactorily explained a patient’s dyspnoea. PAH, pulmona
disease; LHD, left heart disease; sPAPTTE, systolic pulmonary artery pressure at echo
(% predicted); FVC, forced vital capacity (% predicted).the frequency of Raynaud’s phenomenon (P = 0.178) and
calcium channel blocker use (P = 0.128) between the
groups. As expected, the PAH group had significantly
higher sPAPTTE, and significantly lower DLCOcorr and
6MWD compared to the no PH group. Comparing the
PAH and no PH groups, PAH was associated with a sig-
nificantly higher mean ± SD NT-proBNP (1,074 ± 1,506
versus 303 ± 461, P = 0.008) and FVC/DLCOcorr ratio









16 4 3 67.3%
10 0 2 30.6%
0 0 1 2.0%
0 2 0 22.4%
1 0 1 10.2%
algorithm; **patients were considered to have unexplained dypnoea when
ry arterial hypertension; PH, pulmonary hypertension; ILD, interstitial lung
cardiography; DLCO, diffusion capacity of lung for carbon monoxide










Number (n) 17 22 6 4 N/A
Age at onset (y) 56.4 ± 13.4 48.0 ± 12.7 50.7 ± 14.1 42.1 ± 15.9 0.070
Age at study (y) 65.3 ± 9.4 58.8 ± 13.9 62.1 ± 9.2 60.4 ± 13.8 0.060
Disease duration (y) 10.2 ± 8.6 11.1 ± 8.8 11.4 ± 8.9 18.3 ± 15.3 0.785
Female, n (%) 17 (100) 16 (73) 5 (83) 4 (100) 0.027
Male, n (%) 0 (0) 6 (27) 1 (17) 0 (0)
Limited, n (%) 14 (82) 15 (68) 5 (83) 2 (50) 0.464
Diffuse, n (%) 3 (18) 7 (32) 1 (17) 2 (50)
ANA, n (%) 16 (94) 22 (100) 6 (100) 4 (100) 1.00
Anti-Scl70, n (%) 1 (6) 4 (18) 1 (17) 2 (50) 0.374
Anti-cent, n (%) 11 (65) 4 (18) 1 (17) 2 (50) 0.007
ESR (mm/hr) 25.0 ± 18.7 21.0 ± 13.7 25.5 ± 14.0 20.0 ± 8.1 0.696
CRP (mg/L) 11.6 ± 11.3 6.1 ± 7.2 28.6 ± 24.7 3.2 ± 2.2 0.023
WHO FC
1 0 3 0 0 0.008
2 4 13 3 1
3 11 6 2 3
4 2 0 1 0
*Statistical comparisons were made between no PH and PAH groups only, due to the small size of the LHD-PH and ILD-PH groups. PH, pulmonary hypertension;
PAH, pulmonary arterial hypertension; LHD, left heart disease; ILD, interstitial lung disease; ANA, anti-nuclear antibody; anti-Scl70, anti-topoisomerase-1 antibody;
anti-cent, anti-centromere antibody; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; WHO FC, World Health Organization functional class.
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calcium channel blocker use, body mass index (BMI)
and diabetes mellitus, we evaluated these relationships
using simple linear regression. Here we found that that
higher NT-proBNP levels were associated with older ageTable 3 Comparison of investigation parameters between gro
Investigations PAH No PH
TTE parameters
TRV (m/s) 3.5 ± 0.3 2.8 ± 0.4
sPAP (mmHg) 57.7 ± 11.1 38.0 ± 9.9
RHC results
mPAP (mmHg) 34.9 ± 6.9 19.0 ± 3.7
mRAP (mmHg) 9.6 ± 4.0 5.7 ± 3.3
PVR (Wood units) 5.2 ± 2.9 1.6 ± 0.9
PFT results
FVC (% pred) 91.8 ± 15.1 87.0 ± 26.5
DLCOcorr (% pred) 45.9 ± 11.6 61.3 ± 15.6
6MWD (m) 290 ± 117 421 ± 119
FVC/DLCOcorr 2.1 ± 0.5 1.45 ± 0.4
NT-proBNP (pg/mL) 1,074 ± 1,506 303 ± 461
*Statistical comparisons were made between PAH and no PH groups only, due to th
hypertension; PH, pulmonary hypertension; LHD, left heart disease; ILD, interstitial lu
mPAP, mean pulmonary artery pressure; mRAP, mean right atrial pressure; PVR, pul
DLCO, diffusion capacity of lung for carbon monoxide (% predicted); 6MWD, six-min(P <0.0001) and impaired renal function (P = 0.013), whilst
lower NT-proBNP levels were associated with diabetes
mellitus (P = 0.040). In this study, neither calcium channel
blocker use (P = 0.862) nor BMI (P = 0.930) was associated
with NT-proBNP levels.ups
LHD-PH ILD-PH P value*
3.2 ± 0.3 3.4 ± 0.4 <0.0001
48.5 ± 10.5 56.8 ± 15.6 <0.0001
32.0 ± 4.5 32.2 ± 7.3 <0.0001
8.5 ± 3.4 7.2 ± 4.0 0.006
2.1 ± 0.8 5.3 ± 3.5 0.0004
86.5 ± 6.5 49.0 ± 15.0 0.481
59.6 ± 17.7 30.7 ± 9.8 0.001
394 ± 95 330 ± 117 0.004
1.6 ± 0.5 2.0 ± 0.8 0.0001
288 ± 159.9 3,367 ± 3,337 0.0075
e small size of the LHD-PH and ILD-PH groups. PAH, pulmonary arterial
ng disease; TRV, tricuspid regurgitant velocity; sPAP, systolic pulmonary artery;
monary vascular resistance; FVC, forced vital capacity (% predicted);
ute walk distance; NT-proBNP, N-terminal pro-brain natriuretic peptide.
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The PAH, LHD-PH and ILD-PH groups had a compar-
able age at SSc onset, age at the time of study, disease
duration, disease subtype, antibody profile and 6MWD
(all P >0.20). The groups also had a comparable
mPAP (P = 0.527) and mean right atrial pressure (mRAP)
(P = 0.562), but not pulmonary vascular resistance (PVR),
with a significantly higher PVR seen in the PAH group
compared with LHD-PH (P = 0.015). As expected, the
group with ILD-PH had a significantly lower FVC
(P = 0.0005) and DLCO (P = 0.031) than the PAH group.
While the highest absolute NT-proBNP levels were
observed in ILD-PH (3,367 ± 3,337.0 pg/mL), there were
no significant differences in NT-proBNP levels between
the PH groups (P = 0.169). There was also no significant
difference in the FVC/DLCOcorr ratio between the PH
groups (P = 0.261).
Performance of the screening algorithm
The performance of the proposed NT-proBNP and PFT
screening algorithm, as applied to this cohort, is pre-
sented in Table 4. The sensitivity, specificity, PPV and
NPV for PAH were 94.1%, 54.5%, 61.5% and 92.3%,
respectively. In comparison, the sensitivity, specificity,
PPV and NPV of the ESC/ERS guidelines in this co-
hort, were 94.1%, 31.8%, 51.6% and 87.5%. Using the
proposed algorithm, there was only one case of missed
PAH. This patient had an mPAP of 48 mmHg at RHC;
however, the patient was haemodynamically (mRAP 4.5
mmHg, cardiac output (CO) 8.2 L/min and PVR 4.5
Woods units) and functionally (WHO FC II, 6MWD
460 m) well preserved. Of the patients with PAH who
were screen positive, 56% screened positive to NT-Table 4 Performance of screening models for pulmonary arte

















CI, confidence interval; ESC/ERS, European Society of Cardiology/European RespiratoproBNP and PFTs, with 25% screening positive to
NT-proBNP alone, and 19% with PFTs alone.
The performance of the proposed algorithm when
compared with the ESC/ERS guidelines for pre-CPH and
all patients with PH, is also presented in Table 4. As can
be seen, the proposed algorithm was also effective at
screening for pre-CPH and ‘all-cause’ PH; the sensitivity,
specificity, PPV and NPV of the proposed algorithm
for all-cause PH was 88.9%, 54.5%, 70.6% and 80.0%,
respectively.
Alternate case scenario analysis
Due to the higher than expected prevalence of PAH in
this study (as patients had already screened positive to
the ASCS algorithm in order to undergo RHC), we per-
formed an alternate case scenario analysis with a PAH
prevalence of 10%, as commonly reported in the litera-
ture (see Additional file 1) [22]. Here we find that the
adjusted sensitivity, specificity, PPV and NPV of the pro-
posed algorithm for PAH was 94.1%, 54.5%, 18.7% and
98.8%, respectively. For comparison, the adjusted sensi-
tivity, specificity, PPV and NPV of the ESC/ERS algo-
rithm was 94.1%, 31.8%, 13.3% and 98.1%, respectively.
Therefore, our proposed screening model captures al-
most all patients with PAH, and would have reduced the
number of patients referred for echocardiography and
potentially RHC by 50%.
Application of the proposed screening algorithm to
‘no PH’ group
In total, 22 patients were found to have ‘no PH’ at the
time of RHC, despite screening positive on conventional








2.2%, 75.6%) (40.6%, 79.8%) (64.0%, 99.8%)
31.8% 51.6% 87.5%
3.9%, 54.9%) (33.1%, 69.8%) (47.3%, 99.7%)
54.5% 67.7% 85.7%
2.2%, 75.6%) (48.6%, 83.3%) (57.2%, 98.2%)
31.8% 58.3% 77.8%
3.9%, 54.9%) (40.8%, 74.5%) (40.0%, 97.2%)
54.5% 70.6% 80.0%
2.2%, 75.6%) (52.5%, 84.9%) (51.9%, 95.7%)
31.8% 62.5% 77.8%
3.9%, 54.9%) (45.8%, 77.3%) (40.0%, 97.2%)
ry Society.
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these 22 patients being considered for RHC, thereby re-
ducing the number of false positive screens and un-
necessary RHCs. Application of the ESC/ERS algorithm
to this cohort would have led to 15 of 21 being consid-
ered for RHC, with a further patient having an incom-
plete screen due to unrecordable TRV.
Next, we considered the clinical features of the no
PH group according to the proposed algorithm. We
found that those who screened positive but had no PH
were significantly older (67.5 ± 11.7 versus 51.5 ± 9.5,
P = 0.002) and had a higher mPAP at RHC (20.4 ± 3.6
mmHg versus 17.3 ± 3.0, P = 0.041), compared with those
who screened negative. No other important differences
were noted in clinical and laboratory characteristics (in-
cluding disease duration, disease subtype, auto-antibodies
(ANAs) renal function, calcium channel blocker use, BMI,
presence of significant ILD, 6MWD, DLCO or sPAPTTE;
data not shown). Six of the ten patients screening posi-
tively using the proposed algorithm had an mPAP 21 to
24 mmHg consistent with the potentially significant entity,
borderline pulmonary hypertension.
Discussion
In this study, we have confirmed that a screening algo-
rithm comprised of NT-proBNP and PFT is a sensitive,
non-invasive tool for SSc-PAH screening when applied
in patients selected by the more intensive screening
algorithm used in the ASCS. We were also able to show
that compared with the ASCS and the ESC/ERS algo-
rithms, this proposed algorithm could lead to fewer
RHCs being performed, even in those patients with esti-
mated sPAP >40 mmHg on echocardiogram. These re-
sults suggest that rather than referring all patients for
echocardiography ± DLCO, which is the current practice
according to major screening guidelines, only patients
who are ‘positive’ in this ‘first-tier’ screen could be re-
ferred for echocardiography (+/−HRCT, 6WMD and V/Q
if abnormal), and then definitive RHC if PH is still sus-
pected. This requires further validation in a larger group
of SSc patients who have been referred for RHC irrespect-
ive of their apparent risk of having PH. However, the eth-
ical implications of subjecting low-risk patients to RHC
would limit the feasibility of such a study. Nonetheless, it
may be possible to better utilise echocardiography and
rationalise the use of limited resources.
The success of any given screening tool for SSc-PAH
depends on achieving high sensitivity and NPV, ensuring
that there are very few or no missed PAH cases, espe-
cially because of the potentially serious morbidity and
mortality of this complication. At the same time, it is
important to limit the number of false positive screens
to an acceptable level because diagnostic RHC is inva-
sive. The combination of NT-proBNP and PFT achieveda high sensitivity and NPV of 94.1% and 92.3%, re-
spectively, which was at least comparable to the current
ESC/ERS screening guidelines in this cohort, and broadly
comparable to the recently presented DETECT study in
which patients selected for risk of PAH based on DLCO
<60% all had RHC [18]. In fact, the specificity and PPV
achieved with the proposed algorithm was better than that
seen with application of the ERS/ESC guidelines, with
20% fewer patients without PH being referred for RHC.
The decision to perform RHC in this study was based
on screening positive to the ASCS screening algorithm
(detailed in Methods), and the prevalence of PAH in the
highly selected participants in this study was higher than
the usually accepted prevalence of 10%. To account for
this, we performed an ‘alternate case scenario’ analysis,
which confirmed the utility of the screening tool, which
continued to outperform the ERS/ESC model, and would
have led to a reduction in numbers of patients referred for
echocardiography and further tests.
One patient with PAH was not identified using the
proposed screening algorithm. Although this patient was
shown to have an mPAP of 48 mmHg at RHC, haemo-
dynamics and functional status were well preserved and
not typical of moderate PAH (see Results section). How-
ever, this missed PAH case highlights the ongoing need
for having a high level of suspicion in PAH screening.
Indeed, the PFT component of the proposed algorithm
in this patient showed a low and unexplained DLCOcorr
(53% predicted), which in the presence of symptoms,
would almost certainly have triggered further diagnostic
evaluation.
The combination of NT-proBNP with PFTs helps
overcome the limitations of either test performed in iso-
lation. Similar to other studies, we have shown that PAH
cannot be excluded by normal NT-proBNP values and
that NT-proBNP lacks sufficient sensitivity as a stand-
alone test for SSc-PAH [15-17,24]. In addition, whilst a
linear decline in DLCO for over 10 years has been dem-
onstrated in patients, prior to diagnosis of PAH, often
resulting in a high FVC/DLCO ratio, neither DLCO or
FVC/DLCO demonstrates sufficient sensitivity and NPV
to be relied upon for the exclusion of PAH [25,26]. In
this study, we have demonstrated the complementary
roles of NT-proBNP with PFTs, since the absence of ei-
ther component led to a missed PAH diagnosis in 23 to
29%. Thus, NT-proBNP and PFT combine to provide an
efficient and practical ‘first-tier’ screening tool in identi-
fying the SSc patient who should be considered for fur-
ther cardiopulmonary assessment.
Importantly, the proposed screening model shifts
the burden of routine screening away from echocardi-
ography, and instead reserves echocardiography for
high-risk, screen ‘positive’ patients where a detailed as-
sessment (including an assessment of direct and indirect
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(TAPSE), right and left ventricular systolic and diastolic
function, valvular heart disease and pericardial effusion) is
important. In this way, it may be possible to better ration-
alise the use of a limited resource like echocardiography.
This strategy may also prove more cost-effective and
convenient. In Australia, the cost of NT-proBNP com-
bined with PFT is $A197, which is significantly less than
the cost of echocardiography combined with PFT at
$A367. Furthermore, the proposed algorithm would have
resulted in 50% fewer false positive screens in this cohort
with a resultant reduction in the number of RHCs, further
reducing costs and any morbidity associated with this
invasive procedure. NT-proBNP assays have also be-
come much more widely available owing to the use-
fulness of NT-proBNP in the diagnosis, prognosis and risk
stratification of patients with congestive cardiac failure
[27-29]. These factors together suggest that NT-proBNP
together with PFT might be a practical and efficient ‘first-
tier’ screen that better utilises existing resources. A formal
cost-effectiveness analysis is the next step in confirming
these findings.
The usefulness of the proposed algorithm is not lim-
ited to screening for PAH. Multiple causes of pulmonary
hypertension can contribute to dyspnoea in an individual
SSc patient, including ILD-PH and LHD-PH. In addition
to a high sensitivity and NPV, we have shown that the
PPV for all causes of PH is 70.6% using the proposed
algorithm, enabling the clinician to direct further investi-
gation of these patients where appropriate. Further, the
established value of NT-proBNP in identifying cardiac
dysfunction, coupled with the utility of PFTs in the as-
sessment of ILD, makes this algorithm a useful tool for
dyspnoea evaluation in SSc patients.
So far we have considered all patients screening
positive to the proposed algorithm but with no PH at
RHC, as false positives. However, the false positive
patients identified using the proposed algorithm had a
significantly higher mPAP at RHC than those identi-
fied with the existing algorithm, and six of ten pa-
tients considered false positives had borderline PH
with an mPAP of 21 to 24 mmHg. While further
follow-up is required to determine the prognosis of
this group, the ability to identify a subset of patients
widely considered to have abnormal pulmonary artery
pressures remains a desirable feature of our proposed
screening algorithm [30].
While this study provides important observations,
there are some limitations that must be acknowledged.
First, the study participants were an enriched population
selected for RHC on the basis of screening positive to
the ASCS algorithm. To account for this selection bias,
we compared the performance of the ‘proposed’ algo-
rithm with the ESC/ERS guidelines on the same cohort;we also evaluated the performance of the proposed algo-
rithm using an alternate case scenario analysis estimat-
ing the prevalence of PAH at 10% [22]. Therefore, it
remains for the performance of the proposed algorithm
to be evaluated and applied as a first-line screening strat-
egy for SSc-PAH, in a larger study population. Second,
the reported NPV refers only to the high-risk population
selected for RHC. While this is an inherent limitation of
our study design, ethical considerations make it difficult
to perform RHC on patients who have apparently
‘normal’ non-invasive risk assessment for SSc-PAH.
As a result, RHC is generally reserved for evaluation
of patients at high risk for PAH. This has been typ-
ical for most studies that have applied a predefined
screening algorithm for PAH to an unselected popula-
tion of SSc patients [15,31-37]. Even in the recently
published DETECT study, the largest SSc cohort to
undergo RHC, patients were selected for RHC on the
basis of an uncorrected DLCO (% predicted) of less than
60 [18]. The third limitation is that the overall study popu-
lation is small, and the findings need to be confirmed
in a larger population of SSc patients. There was also
only a small number of patients with significant LV
dysfunction across the groups, potentially limiting the
generalisability of the findings to this group. However,
significant LV dysfunction would be expected to raise
NT-proBNP levels, triggering referral of these patients
for echocardiography. Similarly, there were no patients
in the study with an estimated glomerular filtration
rate (eGFR) <30 ml/min, a factor known to raise NT-
proBNP levels. This severity of chronic kidney disease
is not typical for the general SSc patient undergoing
screening; however, it may be more prudent to retain
echocardiography as first-line screening for this group,
particularly given the increased risk of atherosclerotic
cardiovascular disease in this group. Last, the study
does not address the question of the timing and fre-
quency of repeat screening. In keeping with current
international recommendations and emerging evidence,
we would recommend at least annual screening, from the
time of SSc diagnosis [38]. Furthermore, while the study
performed well in this cohort of patients with ‘early’
PAH, the utility of the proposed algorithm for early
PAH remains to be established by using the proposed
algorithm as a first-line screening tool.
Conclusions
We have confirmed that the combination of NT-
proBNP and PFT is a sensitive, yet simple and non-
invasive, screening strategy for SSc-PAH. Patients
screening positive can be referred for echocardiography,
and further confirmatory testing for PAH. In this way, it
would appear possible to rationalise the use of existing
resources.
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